AGN : Analysis & Opinions

  1. Good News for Omeros on OMS302 - Analyst Blog

    July 5, 2013
    The EMA approved the positive opinion rendered by the European Pediatrics Committee related to Omeros' pediatric investigation ...
  2. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was ...
  3. Update on AGN's Acquisition of MAP - Analyst Blog

    February 1, 2013
    Allergan, Inc. (AGN) recently announced that it has commenced a cash tender offer to purchase all the shares of MAP Pharmaceuticals, ...
  4. Allergan's Botox Label Expanded - Analyst Blog

    January 21, 2013
    Allergan Inc. (AGN) recently received a major boost with the US Food and Drug Administration (FDA) approving Botox (onabotulinumtoxinA) ...
  5. Acorda Provides Guidance - Analyst Blog

    January 8, 2013
    Acorda Therapeutics, Inc. (ACOR) recently disclosed unaudited sales of Ampyra (dalfampridine) extended release tablets, 1 ...
  6. Neutral on Sanofi - Analyst Blog

    December 31, 2012
    We are maintaining our Neutral recommendation on Sanofi (SNY). The stock carries a Zacks #3 Rank (Hold) in the short run. ...
  7. Takeda Terminates Amylin Agreement - Analyst Blog

    December 31, 2012
    Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide agreement ...
  8. Acorda Completes Acquisition of Neuronex - Analyst Blog

    December 27, 2012
    Acorda Therapeutics, Inc. (ACOR) recently completed the acquisition of privately-held Neuronex, Inc. As per the agreement ...
  9. Oncothyreon/Merck KGaA Drug Fails - Analyst Blog

    December 27, 2012
    Oncothyreon Inc. (ONTY) and its partner, Merck KGaA (MKGAY) recently presented disappointing data from a phase III trial ...
  10. Pfizer Signs a Couple of Deals - Analyst Blog

    December 26, 2012
    Pfizer (PFE) recently entered into two deals. While one deal was signed with biopharma company Halozyme Therapeutics, Inc. ...
  11. MDT Issues Symplicity Trial Data - Analyst Blog

    December 20, 2012
    Leading medical devices player, Medtronic (MDT) recently announced the online availability of encouraging data from a randomized ...
  12. New Product from Medtronic - Analyst Blog

    December 12, 2012
    Medtronic Inc (MDT), the world's leading spinal technology company, announced the launch of the latest addition to its cervical ...
  13. Generic Launches at Watson Pharma - Analyst Blog

    October 23, 2012
    Watson Pharmaceuticals, Inc. (WPI) recently announced that it has gained US Food and Drug Administration (FDA) approval for ...
  14. Valeant Works Its Mojo With Medicis

    September 7, 2012
    Valeant makes a bold but logical bid for Medicis.
  15. Allergan-Molecular Extend Contracts - Analyst Blog

    August 23, 2012
    Allergan Inc. (AGN) and Molecular Partners AG recently announced the expansion of their existing partnership with two separate ...
  16. Oversold Market Leads To Opportunities

    May 22, 2012
    A market pullback can lead to stocks being on sale.
  17. 6 Overbought Stocks To Watch

    March 30, 2012
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  18. Medicis May Not Stay Independent

    November 10, 2011
    Medicis is well-run, but arguably too risky to stay independent.
  19. Top Drug Stocks

    June 30, 2011
    Recently, three strong factors are driving investors to the drug sector.
  20. Obagi's Pitfalls Provide Investment Opportunity

    May 24, 2011
    Obagi's stock dropped 24% after announcing a 13-cent loss in its first quarter. Find out why this presents an opportunity ...
  21. Medicis - Generic Reprieve And Shareholder Relief

    March 2, 2011
    Medicis gets a big boost from patent settlements.
  22. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  23. Covidien - Better Than People Seem To Think

    November 12, 2010
    With minimal expectations in the stock price, just a little growth at Covidien could make it a market-beater.
  24. An Unsurprising Increase In Biotech Acquisitions

    July 28, 2010
    The Sanofi/Genzyme combination isn't the only biotech M&A activity on the radar.
  25. Novartis Looks For 20/20 Vision With Alcon

    January 11, 2010
    The Swiss drug maker hopes to take full ownership of Alcon later in the year. Find out what it'll mean for these two companies.
Investing News
  1. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  2. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  3. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  4. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  5. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
  6. Can Paying Off Your Mortgage Early Hurt Your Net Worth?

    Saving your money and making double or even triple payments on a mortgage may sound productive, ...
Trading Center